2021-06-300001648257--12-312021Q2false00016482572021-01-012021-06-300001648257us-gaap:CommonStockMember2020-01-012020-06-300001648257us-gaap:RetainedEarningsMember2021-06-300001648257us-gaap:ParentMember2021-06-300001648257us-gaap:NoncontrollingInterestMember2021-06-300001648257us-gaap:AdditionalPaidInCapitalMember2021-06-300001648257us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-06-300001648257us-gaap:RetainedEarningsMember2020-12-310001648257us-gaap:ParentMember2020-12-310001648257us-gaap:NoncontrollingInterestMember2020-12-310001648257us-gaap:AdditionalPaidInCapitalMember2020-12-310001648257us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-12-310001648257us-gaap:RetainedEarningsMember2020-06-300001648257us-gaap:ParentMember2020-06-300001648257us-gaap:NoncontrollingInterestMember2020-06-300001648257us-gaap:AdditionalPaidInCapitalMember2020-06-300001648257us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-06-300001648257us-gaap:RetainedEarningsMember2019-12-310001648257us-gaap:ParentMember2019-12-310001648257us-gaap:NoncontrollingInterestMember2019-12-310001648257us-gaap:AdditionalPaidInCapitalMember2019-12-310001648257us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-12-310001648257hcm:ShanghaiHutchisonPharmaceuticalsLimitedMemberus-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember2019-12-310001648257hcm:HutchisonWhampoaGuangzhouBaiyunshanChineseMedicineCompanyLimitedMemberus-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember2019-12-310001648257currency:USDhcm:BankDepositsMaturingOverThreeMonthsMember2021-06-300001648257currency:HKDhcm:BankDepositsMaturingOverThreeMonthsMember2021-06-300001648257currency:CNYhcm:BankDepositsMaturingOverThreeMonthsMember2021-06-300001648257hcm:BankDepositsMaturingOverThreeMonthsMember2021-06-300001648257currency:USDhcm:BankDepositsMaturingOverThreeMonthsMember2020-12-310001648257currency:HKDhcm:BankDepositsMaturingOverThreeMonthsMember2020-12-310001648257currency:CNYhcm:BankDepositsMaturingOverThreeMonthsMember2020-12-310001648257hcm:BankDepositsMaturingOverThreeMonthsMember2020-12-310001648257us-gaap:SubsequentEventMemberus-gaap:OverAllotmentOptionMember2021-07-120001648257hcm:HCMLShareOptionSchemeMember2019-01-012019-12-310001648257hcm:HCMLShareOptionSchemeMember2019-12-310001648257hcm:ShareOptionScheme2005Member2021-06-300001648257hcm:HCMLShareOptionSchemeMember2020-01-012020-12-310001648257hcm:HCMLShareOptionSchemeMember2020-12-310001648257srt:MinimumMemberhcm:HCMLShareOptionSchemeMember2021-01-012021-06-300001648257srt:MaximumMemberhcm:HCMLShareOptionSchemeMember2021-01-012021-06-300001648257hcm:ShareOptionScheme2005Member2005-06-042005-06-040001648257hcm:OrdinarySharesOrAmericanDepositaryShareMemberhcm:LongTermIncentivePlanMember2021-06-300001648257hcm:OrdinarySharesOrAmericanDepositaryShareMemberhcm:LongTermIncentivePlanMember2020-12-310001648257hcm:OrdinarySharesOrAmericanDepositaryShareMemberhcm:LongTermIncentivePlanMember2019-12-310001648257hcm:AwardsVestingInFourYearsMemberhcm:HCMLShareOptionSchemeMember2021-01-012021-06-300001648257hcm:RelatedPartyTransactionSalesOfGoodsMemberus-gaap:SubsidiaryOfCommonParentMember2021-01-012021-06-300001648257hcm:RelatedPartyTransactionResearchAndDevelopmentServicesMemberus-gaap:EquityMethodInvesteeMember2021-01-012021-06-300001648257hcm:RelatedPartyTransactionSalesOfGoodsMemberus-gaap:SubsidiaryOfCommonParentMember2020-01-012020-06-300001648257hcm:RelatedPartyTransactionResearchAndDevelopmentServicesMemberus-gaap:EquityMethodInvesteeMember2020-01-012020-06-300001648257hcm:ThirdPartiesMemberhcm:OtherVenturesSegmentMember2021-01-012021-06-300001648257hcm:ThirdPartiesMemberhcm:OtherCollaborationRoyaltiesRevenueMember2021-01-012021-06-300001648257hcm:ThirdPartiesMemberhcm:OncologyOrImmunologySegmentMember2021-01-012021-06-300001648257hcm:ThirdPartiesMemberhcm:CollaborationResearchAndDevelopmentMember2021-01-012021-06-300001648257hcm:ResearchAndDevelopmentServicesMemberhcm:OncologyOrImmunologySegmentMember2021-01-012021-06-300001648257hcm:RelatedPartiesMemberhcm:ResearchAndDevelopmentServicesMember2021-01-012021-06-300001648257hcm:RelatedPartiesMemberhcm:OtherVenturesSegmentMember2021-01-012021-06-300001648257hcm:RelatedPartiesMemberhcm:OncologyOrImmunologySegmentMember2021-01-012021-06-300001648257hcm:OtherCollaborationRoyaltiesRevenueMemberhcm:OncologyOrImmunologySegmentMember2021-01-012021-06-300001648257hcm:MarketedProductsMemberhcm:OncologyOrImmunologySegmentMember2021-01-012021-06-300001648257hcm:GoodsDistributionMemberhcm:OtherVenturesSegmentMember2021-01-012021-06-300001648257hcm:CommercializationServicesMemberhcm:OncologyOrImmunologySegmentMember2021-01-012021-06-300001648257hcm:CollaborationResearchAndDevelopmentMemberhcm:OncologyOrImmunologySegmentMember2021-01-012021-06-300001648257us-gaap:IntersegmentEliminationMember2021-01-012021-06-300001648257hcm:ThirdPartiesMember2021-01-012021-06-300001648257hcm:ResearchAndDevelopmentServicesMember2021-01-012021-06-300001648257hcm:RelatedPartiesMember2021-01-012021-06-300001648257hcm:OtherVenturesSegmentMember2021-01-012021-06-300001648257hcm:OtherCollaborationRoyaltiesRevenueMember2021-01-012021-06-300001648257hcm:OncologyOrImmunologySegmentMember2021-01-012021-06-300001648257hcm:MarketedProductsMember2021-01-012021-06-300001648257hcm:GoodsDistributionMember2021-01-012021-06-300001648257hcm:CommercializationServicesMember2021-01-012021-06-300001648257hcm:CollaborationResearchAndDevelopmentMember2021-01-012021-06-300001648257hcm:ThirdPartiesMemberhcm:OtherVenturesSegmentMember2020-01-012020-06-300001648257hcm:ThirdPartiesMemberhcm:OtherCollaborationRoyaltiesRevenueMember2020-01-012020-06-300001648257hcm:ThirdPartiesMemberhcm:OncologyOrImmunologySegmentMember2020-01-012020-06-300001648257hcm:ThirdPartiesMemberhcm:CollaborationResearchAndDevelopmentMember2020-01-012020-06-300001648257hcm:ResearchAndDevelopmentServicesMemberhcm:OncologyOrImmunologySegmentMember2020-01-012020-06-300001648257hcm:RelatedPartiesMemberhcm:ResearchAndDevelopmentServicesMember2020-01-012020-06-300001648257hcm:RelatedPartiesMemberhcm:OtherVenturesSegmentMember2020-01-012020-06-300001648257hcm:RelatedPartiesMemberhcm:OncologyOrImmunologySegmentMember2020-01-012020-06-300001648257hcm:OtherCollaborationRoyaltiesRevenueMemberhcm:OncologyOrImmunologySegmentMember2020-01-012020-06-300001648257hcm:MarketedProductsMemberhcm:OncologyOrImmunologySegmentMember2020-01-012020-06-300001648257hcm:GoodsDistributionMemberhcm:OtherVenturesSegmentMember2020-01-012020-06-300001648257hcm:CollaborationResearchAndDevelopmentMemberhcm:OncologyOrImmunologySegmentMember2020-01-012020-06-300001648257us-gaap:IntersegmentEliminationMember2020-01-012020-06-300001648257hcm:ThirdPartiesMember2020-01-012020-06-300001648257hcm:ResearchAndDevelopmentServicesMember2020-01-012020-06-300001648257hcm:RelatedPartiesMember2020-01-012020-06-300001648257hcm:OtherVenturesSegmentMember2020-01-012020-06-300001648257hcm:OtherCollaborationRoyaltiesRevenueMember2020-01-012020-06-300001648257hcm:OncologyOrImmunologySegmentMember2020-01-012020-06-300001648257hcm:MarketedProductsMember2020-01-012020-06-300001648257hcm:GoodsDistributionMember2020-01-012020-06-300001648257hcm:CollaborationResearchAndDevelopmentMember2020-01-012020-06-300001648257hcm:CollaborativeArrangementsMember2021-01-012021-06-300001648257hcm:CollaborativeArrangementsMember2020-01-012020-06-300001648257us-gaap:EquityMethodInvesteeMember2021-01-012021-06-300001648257us-gaap:EquityMethodInvesteeMember2020-01-012020-06-300001648257hcm:RelatedPartyTransactionMarketingServicesMemberus-gaap:SubsidiaryOfCommonParentMember2021-01-012021-06-300001648257hcm:RelatedPartyTransactionManagementServiceMemberus-gaap:SubsidiaryOfCommonParentMember2021-01-012021-06-300001648257hcm:RelatedPartyTransactionMarketingServicesMemberus-gaap:SubsidiaryOfCommonParentMember2020-01-012020-06-300001648257hcm:RelatedPartyTransactionManagementServiceMemberus-gaap:SubsidiaryOfCommonParentMember2020-01-012020-06-300001648257hcm:AllOtherEquityMethodInvesteesMember2021-01-012021-06-300001648257hcm:AllOtherEquityMethodInvesteesMember2020-01-012020-06-300001648257us-gaap:SubsequentEventMemberus-gaap:OverAllotmentOptionMember2021-07-122021-07-120001648257us-gaap:CommonStockMemberhcm:FurtherPublicOfferingMember2021-06-302021-06-300001648257us-gaap:CommonStockMember2021-04-142021-04-140001648257us-gaap:UnsecuredDebtMemberus-gaap:NotesPayableToBanksMember2019-05-012019-05-310001648257hcm:NonControllingShareholdersOfSubsidiariesMemberhcm:LoanPayableToNonControllingShareholdersOfSubsidiariesMember2020-12-310001648257us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-01-012021-06-300001648257us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-01-012020-06-300001648257us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMemberus-gaap:CapitalAdditionsMember2021-01-012021-06-300001648257us-gaap:CapitalAdditionsMember2021-01-012021-06-300001648257us-gaap:RevolvingCreditFacilityMember2020-08-310001648257us-gaap:UnsecuredDebtMemberus-gaap:RevolvingCreditFacilityMember2019-05-310001648257us-gaap:UnsecuredDebtMemberus-gaap:NotesPayableToBanksMember2019-05-310001648257us-gaap:UnsecuredDebtMember2019-05-310001648257us-gaap:RevolvingCreditFacilityMember2018-11-300001648257us-gaap:UnsecuredDebtMemberus-gaap:RevolvingCreditFacilityMember2021-06-300001648257us-gaap:RevolvingCreditFacilityMember2021-06-300001648257us-gaap:UnsecuredDebtMemberus-gaap:RevolvingCreditFacilityMember2020-12-310001648257us-gaap:RevolvingCreditFacilityMember2020-12-310001648257srt:WeightedAverageMemberus-gaap:BankTimeDepositsMember2021-06-300001648257srt:WeightedAverageMemberhcm:BankDepositsMaturingOverThreeMonthsMember2021-06-300001648257srt:WeightedAverageMemberus-gaap:BankTimeDepositsMember2020-12-310001648257srt:WeightedAverageMemberhcm:BankDepositsMaturingOverThreeMonthsMember2020-12-310001648257hcm:ShanghaiHutchisonPharmaceuticalsLimitedMember2021-06-300001648257hcm:HutchisonWhampoaGuangzhouBaiyunshanChineseMedicineCompanyLimitedMember2021-06-300001648257hcm:AllOtherEquityMethodInvesteesMember2021-06-300001648257hcm:ShanghaiHutchisonPharmaceuticalsLimitedMember2020-12-310001648257hcm:HutchisonWhampoaGuangzhouBaiyunshanChineseMedicineCompanyLimitedMember2020-12-310001648257hcm:AllOtherEquityMethodInvesteesMember2020-12-310001648257hcm:HutchisonWhampoaGuangzhouBaiyunshanChineseMedicineCompanyLimitedMemberus-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember2020-06-300001648257hcm:ShanghaiHutchisonPharmaceuticalsLimitedMemberus-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember2020-06-300001648257hcm:HCMLShareOptionSchemeMember2021-06-300001648257hcm:RelatedPartyTransactionDividendReceivableMemberus-gaap:EquityMethodInvesteeMember2021-06-300001648257hcm:RelatedPartyTransactionDividendReceivableMemberus-gaap:EquityMethodInvesteeMember2020-12-310001648257hcm:ShanghaiHutchisonPharmaceuticalsLimitedMemberus-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember2021-01-012021-06-300001648257hcm:HutchisonWhampoaGuangzhouBaiyunshanChineseMedicineCompanyLimitedMemberus-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember2021-01-012021-06-300001648257hcm:ShanghaiHutchisonPharmaceuticalsLimitedMemberus-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember2020-01-012020-06-300001648257hcm:LongTermIncentivePlanMember2021-06-300001648257hcm:LongTermIncentivePlanMember2020-12-310001648257us-gaap:RevolvingCreditFacilityMember2020-08-012020-08-310001648257us-gaap:UnsecuredDebtMember2019-05-012019-05-310001648257us-gaap:RevolvingCreditFacilityMember2018-11-012018-11-300001648257us-gaap:RevolvingCreditFacilityMemberhcm:HongKongInterbankOfferedRateMember2020-08-012020-08-310001648257us-gaap:UnsecuredDebtMemberhcm:HongKongInterbankOfferedRateMember2019-05-012019-05-310001648257us-gaap:UnsecuredDebtMemberus-gaap:RevolvingCreditFacilityMemberhcm:HongKongInterbankOfferedRateMember2018-11-012018-11-300001648257hcm:UnitedStatesAndOthersMember2021-01-012021-06-300001648257country:HK2021-01-012021-06-300001648257country:CN2021-01-012021-06-300001648257hcm:UnitedStatesAndOthersMember2020-01-012020-06-300001648257country:HK2020-01-012020-06-300001648257country:CN2020-01-012020-06-300001648257hcm:ThirdPartiesMemberus-gaap:ProductMember2021-01-012021-06-300001648257hcm:ThirdPartiesMemberhcm:CommercializationServicesMember2021-01-012021-06-300001648257hcm:RelatedPartiesMemberus-gaap:ProductMember2021-01-012021-06-300001648257hcm:ThirdPartiesMemberus-gaap:ProductMember2020-01-012020-06-300001648257hcm:RelatedPartiesMemberus-gaap:ProductMember2020-01-012020-06-300001648257us-gaap:CommonStockMember2021-06-300001648257us-gaap:CommonStockMember2020-12-310001648257us-gaap:CommonStockMember2020-06-300001648257us-gaap:CommonStockMember2019-12-310001648257currency:USD2021-06-300001648257currency:HKD2021-06-300001648257currency:GBP2021-06-300001648257currency:EUR2021-06-300001648257currency:CNY2021-06-300001648257currency:USD2020-12-310001648257currency:HKD2020-12-310001648257currency:GBP2020-12-310001648257currency:EUR2020-12-310001648257currency:CNY2020-12-310001648257hcm:HutchisonWhampoaGuangzhouBaiyunshanChineseMedicineCompanyLimitedMember2020-06-300001648257hcm:ShanghaiHutchisonPharmaceuticalsLimitedMemberus-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember2021-06-300001648257hcm:HutchisonWhampoaGuangzhouBaiyunshanChineseMedicineCompanyLimitedMemberus-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember2021-06-300001648257hcm:ShanghaiHutchisonPharmaceuticalsLimitedMemberus-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember2020-12-310001648257hcm:HutchisonWhampoaGuangzhouBaiyunshanChineseMedicineCompanyLimitedMemberus-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember2020-12-310001648257us-gaap:OperatingSegmentsMemberhcm:UnitedStatesAndOthersMemberhcm:OncologyOrImmunologySegmentMemberhcm:ResearchAndDevelopmentSubsegmentMember2021-06-300001648257us-gaap:OperatingSegmentsMembercountry:CNhcm:OncologyOrImmunologySegmentMemberhcm:MarketedProductsSubsegmentMember2021-06-300001648257us-gaap:OperatingSegmentsMembercountry:CNhcm:OtherVenturesSegmentMember2021-06-300001648257hcm:CorporateAndReconcilingItemsMember2021-06-300001648257us-gaap:OperatingSegmentsMemberhcm:UnitedStatesAndOthersMemberhcm:OncologyOrImmunologySegmentMemberhcm:ResearchAndDevelopmentSubsegmentMember2020-12-310001648257us-gaap:OperatingSegmentsMembercountry:CNhcm:OncologyOrImmunologySegmentMemberhcm:MarketedProductsSubsegmentMember2020-12-310001648257us-gaap:OperatingSegmentsMembercountry:CNhcm:OtherVenturesSegmentMember2020-12-310001648257hcm:CorporateAndReconcilingItemsMember2020-12-310001648257hcm:HutchisonWhampoaGuangzhouBaiyunshanChineseMedicineCompanyLimitedMemberus-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember2020-01-012020-06-3000016482572020-06-3000016482572019-12-310001648257us-gaap:SellingGeneralAndAdministrativeExpensesMemberhcm:LongTermIncentivePlanMember2021-01-012021-06-300001648257us-gaap:SellingGeneralAndAdministrativeExpensesMemberhcm:HCMLShareOptionSchemeMember2021-01-012021-06-300001648257us-gaap:ResearchAndDevelopmentExpenseMemberhcm:LongTermIncentivePlanMember2021-01-012021-06-300001648257us-gaap:ResearchAndDevelopmentExpenseMemberhcm:HCMLShareOptionSchemeMember2021-01-012021-06-300001648257us-gaap:LiabilityMemberhcm:LongTermIncentivePlanMember2021-01-012021-06-300001648257us-gaap:CostOfSalesMemberhcm:LongTermIncentivePlanMember2021-01-012021-06-300001648257us-gaap:CostOfSalesMemberhcm:HCMLShareOptionSchemeMember2021-01-012021-06-300001648257us-gaap:AdditionalPaidInCapitalMemberhcm:LongTermIncentivePlanMember2021-01-012021-06-300001648257us-gaap:SellingGeneralAndAdministrativeExpensesMemberhcm:LongTermIncentivePlanMember2020-01-012020-06-300001648257us-gaap:SellingGeneralAndAdministrativeExpensesMemberhcm:HCMLShareOptionSchemeMember2020-01-012020-06-300001648257us-gaap:ResearchAndDevelopmentExpenseMemberhcm:LongTermIncentivePlanMember2020-01-012020-06-300001648257us-gaap:ResearchAndDevelopmentExpenseMemberhcm:HCMLShareOptionSchemeMember2020-01-012020-06-300001648257us-gaap:LiabilityMemberhcm:LongTermIncentivePlanMember2020-01-012020-06-300001648257us-gaap:CostOfSalesMemberhcm:LongTermIncentivePlanMember2020-01-012020-06-300001648257us-gaap:CostOfSalesMemberhcm:HCMLShareOptionSchemeMember2020-01-012020-06-300001648257us-gaap:AdditionalPaidInCapitalMemberhcm:LongTermIncentivePlanMember2020-01-012020-06-300001648257hcm:HCMLShareOptionSchemeMember2020-01-012020-06-300001648257us-gaap:NoncontrollingInterestMember2021-01-012021-06-300001648257us-gaap:NoncontrollingInterestMember2020-01-012020-06-300001648257us-gaap:SubsidiaryOfCommonParentMember2021-06-300001648257us-gaap:SubsidiaryOfCommonParentMember2020-12-310001648257hcm:NotLaterThanThreeMonthsMember2021-06-300001648257hcm:NonControllingShareholdersOfSubsidiariesMember2021-06-300001648257hcm:LaterThanOneYearMember2021-06-300001648257hcm:BetweenThreeMonthsToSixMonthsMember2021-06-300001648257hcm:BetweenSixMonthsToOneYearMember2021-06-300001648257hcm:NotLaterThanThreeMonthsMember2020-12-310001648257hcm:NonControllingShareholdersOfSubsidiariesMember2020-12-310001648257hcm:LaterThanOneYearMember2020-12-310001648257hcm:BetweenThreeMonthsToSixMonthsMember2020-12-310001648257hcm:BetweenSixMonthsToOneYearMember2020-12-310001648257us-gaap:ParentMember2020-01-012020-06-300001648257us-gaap:RetainedEarningsMember2021-01-012021-06-300001648257us-gaap:RetainedEarningsMember2020-01-012020-06-300001648257us-gaap:AdditionalPaidInCapitalMember2020-01-012020-06-300001648257srt:ParentCompanyMemberhcm:HutchisonWhampoaGuangzhouBaiyunshanChineseMedicineCompanyLimitedMember2021-03-012021-03-310001648257srt:MinimumMemberhcm:BankDepositsMaturingOverThreeMonthsMember2021-01-012021-06-300001648257srt:MaximumMemberhcm:BankDepositsMaturingOverThreeMonthsMember2021-01-012021-06-300001648257srt:MinimumMemberhcm:BankDepositsMaturingOverThreeMonthsMember2020-01-012020-12-310001648257srt:MaximumMemberhcm:BankDepositsMaturingOverThreeMonthsMember2020-01-012020-12-310001648257us-gaap:ParentMember2021-01-012021-06-300001648257us-gaap:AdditionalPaidInCapitalMember2021-01-012021-06-300001648257us-gaap:CommonStockMember2021-01-012021-06-300001648257hcm:LongTermIncentivePlanMember2020-01-012020-06-300001648257hcm:AwardsVestingInFourYearsMemberhcm:HCMLShareOptionSchemeMember2021-06-300001648257hcm:HCMLShareOptionSchemeMember2021-01-012021-06-300001648257hcm:VestingBasedOnPerformanceMemberhcm:LongTermIncentivePlanMember2021-03-262021-03-260001648257hcm:VestingBasedOnPerformanceMemberhcm:LongTermIncentivePlanMember2020-08-122020-08-120001648257hcm:VestingBasedOnPerformanceMemberhcm:LongTermIncentivePlanMember2020-04-202020-04-200001648257hcm:VestingBasedOnNonPerformanceMemberhcm:LongTermIncentivePlanMember2020-04-202020-04-200001648257hcm:VestingBasedOnPerformanceMemberhcm:GrantDateMarch2021Memberhcm:LongTermIncentivePlanMember2021-03-260001648257hcm:VestingBasedOnPerformanceMemberhcm:GrantDateAugust2020TwoMemberhcm:LongTermIncentivePlanMember2020-08-120001648257hcm:VestingBasedOnPerformanceMemberhcm:GrantDateAugust2020OneMemberhcm:LongTermIncentivePlanMember2020-08-120001648257hcm:VestingBasedOnPerformanceMemberhcm:GrantDateApril202020TwoMemberhcm:LongTermIncentivePlanMember2020-04-200001648257hcm:VestingBasedOnPerformanceMemberhcm:GrantDateApril202020ThreeMemberhcm:LongTermIncentivePlanMember2020-04-200001648257hcm:VestingBasedOnPerformanceMemberhcm:GrantDateApril202020OneMemberhcm:LongTermIncentivePlanMember2020-04-200001648257hcm:VestingBasedOnPerformanceMemberhcm:GrantDateApril202020FourMemberhcm:LongTermIncentivePlanMember2020-04-200001648257hcm:OrdinarySharesOrAmericanDepositaryShareMemberhcm:LongTermIncentivePlanMember2020-01-012020-12-310001648257hcm:OrdinarySharesOrAmericanDepositaryShareMemberhcm:LongTermIncentivePlanMember2021-01-012021-06-300001648257hcm:OrdinarySharesOrAmericanDepositaryShareMemberhcm:LongTermIncentivePlanMember2020-01-012020-06-300001648257hcm:LongTermIncentivePlanMember2021-01-012021-06-300001648257us-gaap:SubsidiaryOfCommonParentMember2021-01-012021-06-300001648257us-gaap:SubsidiaryOfCommonParentMember2020-01-012020-12-310001648257us-gaap:EquityMethodInvesteeMember2021-06-300001648257us-gaap:EquityMethodInvesteeMember2020-12-310001648257us-gaap:OperatingSegmentsMemberhcm:UnitedStatesAndOthersMemberhcm:OncologyOrImmunologySegmentMemberhcm:ResearchAndDevelopmentSubsegmentMember2021-01-012021-06-300001648257us-gaap:OperatingSegmentsMembercountry:CNhcm:OncologyOrImmunologySegmentMemberhcm:ResearchAndDevelopmentSubsegmentMember2021-01-012021-06-300001648257us-gaap:OperatingSegmentsMembercountry:CNhcm:OncologyOrImmunologySegmentMemberhcm:MarketedProductsSubsegmentMember2021-01-012021-06-300001648257us-gaap:OperatingSegmentsMemberhcm:OncologyOrImmunologySegmentMemberhcm:ResearchAndDevelopmentSubsegmentMember2021-01-012021-06-300001648257us-gaap:OperatingSegmentsMembercountry:CNhcm:OtherVenturesSegmentMember2021-01-012021-06-300001648257us-gaap:OperatingSegmentsMemberhcm:OncologyOrImmunologySegmentMember2021-01-012021-06-300001648257hcm:CorporateAndReconcilingItemsMember2021-01-012021-06-300001648257us-gaap:OperatingSegmentsMemberhcm:UnitedStatesAndOthersMemberhcm:OncologyOrImmunologySegmentMemberhcm:ResearchAndDevelopmentSubsegmentMember2020-01-012020-06-300001648257us-gaap:OperatingSegmentsMembercountry:CNhcm:OncologyOrImmunologySegmentMemberhcm:ResearchAndDevelopmentSubsegmentMember2020-01-012020-06-300001648257us-gaap:OperatingSegmentsMembercountry:CNhcm:OncologyOrImmunologySegmentMemberhcm:MarketedProductsSubsegmentMember2020-01-012020-06-300001648257us-gaap:OperatingSegmentsMemberhcm:OncologyOrImmunologySegmentMemberhcm:ResearchAndDevelopmentSubsegmentMember2020-01-012020-06-300001648257us-gaap:OperatingSegmentsMembercountry:CNhcm:OtherVenturesSegmentMember2020-01-012020-06-300001648257us-gaap:OperatingSegmentsMemberhcm:OncologyOrImmunologySegmentMember2020-01-012020-06-300001648257hcm:CorporateAndReconcilingItemsMember2020-01-012020-06-300001648257hcm:OneCustomerMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMemberhcm:OtherVenturesSegmentMember2021-01-012021-06-300001648257hcm:OneCustomerMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMemberhcm:OncologyOrImmunologySegmentMember2021-01-012021-06-300001648257hcm:OneCustomerMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMemberhcm:OtherVenturesSegmentMember2020-01-012020-06-300001648257hcm:OneCustomerMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMemberhcm:OncologyOrImmunologySegmentMember2020-01-012020-06-300001648257us-gaap:OperatingSegmentsMembercountry:CNhcm:OncologyOrImmunologySegmentMemberhcm:ResearchAndDevelopmentSubsegmentMember2021-06-300001648257us-gaap:OperatingSegmentsMemberhcm:OncologyOrImmunologySegmentMemberhcm:ResearchAndDevelopmentSubsegmentMember2021-06-300001648257us-gaap:OperatingSegmentsMemberhcm:OncologyOrImmunologySegmentMember2021-06-300001648257us-gaap:OperatingSegmentsMembercountry:CNhcm:OncologyOrImmunologySegmentMemberhcm:ResearchAndDevelopmentSubsegmentMember2020-12-310001648257us-gaap:OperatingSegmentsMemberhcm:OncologyOrImmunologySegmentMemberhcm:ResearchAndDevelopmentSubsegmentMember2020-12-310001648257us-gaap:OperatingSegmentsMemberhcm:OncologyOrImmunologySegmentMember2020-12-310001648257hcm:HutchisonWhampoaGuangzhouBaiyunshanChineseMedicineCompanyLimitedMember2020-11-012020-11-300001648257hcm:ShanghaiHutchisonPharmaceuticalsLimitedMember2021-01-012021-06-300001648257hcm:HutchisonWhampoaGuangzhouBaiyunshanChineseMedicineCompanyLimitedMember2021-01-012021-06-300001648257hcm:NonControllingShareholdersOfSubsidiariesMember2021-01-012021-06-300001648257hcm:NonControllingShareholdersOfSubsidiariesMember2020-01-012020-06-300001648257hcm:HutchisonWhampoaGuangzhouBaiyunshanChineseMedicineCompanyLimitedMember2021-06-012021-06-300001648257hcm:HutchisonWhampoaGuangzhouBaiyunshanChineseMedicineCompanyLimitedMember2021-03-012021-03-3100016482572020-01-012020-06-300001648257hcm:SeroquelMember2021-06-3000016482572021-06-3000016482572020-12-31hcm:claimiso4217:GBPxbrli:sharesiso4217:GBPiso4217:HKDxbrli:sharesiso4217:USDiso4217:CNYxbrli:purehcm:areahcm:customerhcm:Votexbrli:sharesiso4217:USDxbrli:sharesiso4217:HKD

​

​

​

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13A-16 OR 15D-16 UNDER

THE SECURITIES EXCHANGE ACT OF 1934

For the Month of July 2021

Commission File Number: 001-37710

HUTCHMED (CHINA) LIMITED

(Translation of registrant’s name into English)

48th Floor, Cheung Kong Center, 2 Queen’s Road Central, Hong Kong

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F ⌧ Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

Note: Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

Note: Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant’s “home country”), or under the rules of the home country exchange on which the registrant’s securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant’s security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.

​

​

​

​

HUTCHMED (CHINA) LIMITED

Form 6-K

EXHIBIT INDEX

​

​

​

​

Exhibit No.

    

Description

Exhibit 99.1

​

Announcement relating to unaudited financial results as of and for the six months ended June 30, 2021

Exhibit 99.2

​

HUTCHMED (China) Limited supplemental disclosures

​

​

​

​

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

​

​

​

​

​

HUTCHMED (CHINA) LIMITED

​

​

​

​

​

​

​

By:

/s/ JOHNNY CHENG

​

​

Name:

Johnny Cheng

​

​

Title:

Chief Financial Officer

​

Date: 28 July 2021

​

​